Pharmacy

After two decades of no available Lyme disease vaccine, Pfizer is vying to enter the market with a $25 million phase 3 trial for its candidate.

Pfizer nabbed a $5.4 billion deal to acquire sickle cell drugmaker Global Blood Therapeutics, according to an Aug. 8 press release. 

The approval of a fourth COVID-19 vaccine won't "make a real dent" in America's vaccination rate, infectious disease experts told ABC News in an Aug. 5 report. 

Access to reproductive health products has gotten murkier after a Minnesota jury ruled in favor of a pharmacist who refused to sell contraceptives in 2019 because of his beliefs, according to MPR News. 

Drug manufacturer Eli Lilly, one of Indiana's largest employers, said it plans to seek growth opportunities outside of Indiana following the signing of an abortion ban bill, FOX59 reported on Aug. 6. 

Thousand Oaks, Calif.-based pharmaceutical company Amgen will acquire ChemoCentryx and its autoimmune drug, Tavneos, for an all-cash payment of $3.7 billion, according to an Aug. 4 news release from Amgen. 

After more than two years of the COVID-19 pandemic and the resurgence of a global monkeypox outbreak, here's where six major pharmaceutical companies stand after 2022's second quarter:

Indianapolis-based Eli Lilly will sell its COVID-19 monoclonal antibody treatment to healthcare systems, hospitals and states this month, The Wall Street Journal reported Aug. 3. 

Eli Lilly must shell out $61.2 million to Illinois after a jury found the Indianapolis-based pharmaceutical company made false Medicaid claims through omitting average manufacturer prices in its calculations, court documents show.

Biopharmaceutical company Gilead Sciences has agreed to acquire MiroBio, a biotechnology company focused on the research of cellular immunity.